Trial Profile
A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary) ; Anthracyclines; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms BLAST
- 13 Dec 2022 Primary endpoint has not been met (Relapse Free Survival time), as per Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 23 Nov 2020 According to an BioLineRx media release, as the study did not demonstrate statistically significant effect in primary endpoint; DMC recommended not to continue the study